Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of TRI-611 in advanced ALK-positive non-small cell lung cancer
2025-524418-27-00Phase 2Authorised
- Sponsor
- TRIANA Biomedicines
- Start
- Oct 2026
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of TRI-611 in non-small cell lung cancer (NSCLC), sponsored by TRIANA Biomedicines. Primary endpoints: Overall safety profile and Objective response rate and depth of response. Planned start Oct 2026; status: authorised.
02
Drugs
TRI-611
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-524418-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524418-27-00.